Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has recently added a key international opinion leader to its Scientific Advisory Board. Mark Freedman, M.D., is a professor of medicine in the field of neurology at the University of Ottawa, and director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He will be joining other colleagues of high regard on Opexa’s Scientific Advisory Board: Dawn McGuire, M.D. (Chair), Doug Arnold, M.D., Edward Fox, M.D., Ph.D., Hans-Peter Hartung, M.D., Clyde Markowitz, M.D., Paul O’Connor, M.D., and Arthur Vandenbark, Ph.D.
“It is a distinct pleasure to welcome Dr. Freedman to Opexa’s Scientific Advisory Board,” stated Dr. McGuire, Chair of the SAB. “Dr. Freedman is internationally renowned for his expertise in MS translational research and has been involved in numerous clinical trials in patients with MS. We will benefit greatly from his clinical and scientific insights as we move to the next phase of Tovaxin development for MS.”
“As a neuroimmunologist, I have carefully followed Opexa’s technology for some time and have always been intrigued about this novel approach to treating MS patients,” commented Dr. Freedman. “As a personalized and targeted therapy with an excellent safety profile, Tovaxin may prove to be a differentiated product for the treatment of both Relapsing Remitting and Secondary Progressive MS patients. I look forward to using my knowledge and experience to guide the Company in their efforts to further develop Tovaxin for patients with MS.”
Mark Freedman, M.D. Bio
Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of the American Academy of Neurology (FAAN).